Study Enrollment

Your details will not be published or shared.

Clinical Trial

MEI-011: A Two-Stage, Open-Label Followed by Placebo Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents

The purpose of this study is to learn how the investigational drug, called Pracinostat, works, including how safe it is when given with the approved drug, Azacitidine, in subjects diagnosed with advanced myelodysplastic syndrome (MDS).

Eligibility Criteria

  • - Male or female 18 years of age or older - Diagnosis of Myelodysplastic Syndrome (MDS) - Treatment with approved drug, Azacitidine, must be indicated

Contact Information

    Connie Edwards, RN, ADN

    (706) 721-0734